Efficacy of drug-eluting beads transarterial chemoembolization in the treatment of liver metastases from gastrointestinal stromal tumors with targeted therapy failure
Objective To explore the efficacy and safety of CalliSpheres drug-eluting beads transarterial chemoembolization(DEB-TACE)in the treatment of unresectable liver metastases from gastrointestinal stromal tumors with targeted therapy failure.Methods From March 2019 to March 2022,27 patients with unresectable liver metastases from gastrointestinal stromal tumors admitted to Linyi Cancer Hospital who had failed at least second-line targeted therapy were retrospectively analyzed.All patients received CalliSpheres DEB-TACE.Modified response evaluation criteria in solid tumors(mRECIST)was used to evaluate the tumor response after DEB-TACE.Overall survival time(OS),progression-free survival time(PFS),and adverse reactions during treatment were analyzed.Results CT/MRI performed 5-7 days after DEB-TACE showed obvious tumor necrosis.According to mRECIST,the objective remission rate(ORR)and disease control rate(DCR)were 96.29％and 100.00％,respectively,2 months after DEB-TACE surgery.The median PFS was 11.0 months and the median OS was 16.0 months.The main adverse reactions after DEB-TACE were fever,pain,nausea and vomiting,etc.Most of the complications were mild and were relieved by symptomatic treatment.No serious complications such as CalliSpheres drug-eluting beads-related liver abscess and ectopic embolism occurred.Conclusion DEB-TACE is a safe and feasible treatment for unresectable liver metastases of gastrointestinal stromal tumors with targeted therapy failure,which has good efficacy and low adverse reactions.It is worthy of clinical promotion and application.
万方数据
维普
